Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster. 1980

E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D005260 Female Females
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
April 1984, European journal of cancer & clinical oncology,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
January 2005, Medicinal research reviews,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
June 1979, Proceedings of the National Academy of Sciences of the United States of America,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
June 1988, Journal of chromatography,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
August 1984, The Journal of antimicrobial chemotherapy,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
January 1980, Antimicrobial agents and chemotherapy,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
December 1988, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
August 1979, Antimicrobial agents and chemotherapy,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
April 1987, Molecular pharmacology,
E de Clercq, and H Degreef, and J Wildiers, and G de Jonge, and A Drochmans, and J Descamps, and P de Somer
January 1985, Antiviral research,
Copied contents to your clipboard!